Panelists explore recent findings of the PATHFINDER study, focusing on the objectives, study design, key results, and differences from previous studies, shedding light on the potential of early cancer detection tests.
Quanterix Announces New Agreement to Advance Blood Based Alzheimer s Disease Detection lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
Agreement provides Quanterix a license to extensively studied p-Tau 217 antibodies to enable global access to plasma-based testing for Alzheimer's Disease research and diagnostics Quanterix Corporation (NASDAQ:QTRX),
What You Should Know: PathAI Diagnostics, formerly Poplar Healthcare, a leading laboratory services company, today unveiled the world’s first AI-assisted laboratory-developed test for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH).MASLD and
Trip Taylor, IR Thank you, operator. I would like to remind everyone that comments made by management today and answers to questions will include forward-looking.